Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.32 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21808534 | 1.00 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL1404442 | 1.00 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL16178433 | 0.98 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL6336086 | 0.98 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL4686451 | 0.91 | SLC6A1 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL30686962 | 0.87 | SLC6A1 (0.39) | SLC6A1SLC6A11SLC6A13TSHRLMNA | |
| SCHEMBL23406750 | 0.85 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL22799163 | 0.85 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL3710945 | 0.81 | CHRM2 (0.31) | NOTUM | |
| SCHEMBL16824955 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | ANGEX PHARMACEUTICAL, INC. (US) | 2022-06-14 | — | — | US | claimed |
| US-20210163445-A1 | CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2021-06-03 | — | — | US | claimed |
| EP-3727364-A1 | CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS | Angex Pharmaceutical, Inc. (US) | 2020-10-28 | — | — | EP | claimed |
| CN-118666869-A | Bridged ring compounds, pharmaceutical composition and application thereof | 上海湃隆生物科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118561872-A | Pyrimido-pyridine biological inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240226098-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2023141570-A9 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-118221698-A | KRAS G12D inhibitors | 艾立康药业股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240199650-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| US-9359371-B2 | Bicyclic substituted pyrimidine compounds | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| WO-2016034637-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016027195-A1 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | PFIZER INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| US-20160052930-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2016-02-25 | — | — | US | disclosed |
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2015-08-20 | — | — | US | disclosed |
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| EP-2886540-A1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-24 | — | — | EP | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226098-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | CHRNB2 2665/4885CHRNB4 2436/4885CHRNA3 2868/4885 |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | CHRNB2 4410/4885CHRNB4 4108/4885CHRNA3 4371/4885 |
| US-20240199650-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | KRAS, NRAS, DPYD | CHRNB2 3957/4885CHRNB4 4075/4885CHRNA3 4129/4885 |
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | DPYD, UMPS, TYMP | CHRNB2 3775/4885CHRNB4 3678/4885CHRNA3 3080/4885 |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | CHRNB2 4870/4885CHRNB4 4878/4885CHRNA3 4877/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CHRNB2 4503/4885CHRNB4 4564/4885CHRNA3 4431/4885 |
| US-20160052930-A1 | AMINOPYRIMIDINYL COMPOUNDS | CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3 | CHRNB2 719/4885CHRNB4 578/4885CHRNA3 73/4885 |
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | UCK2, ULK2, CDK9 | CHRNB2 4796/4885CHRNB4 4823/4885CHRNA3 4655/4885 |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | CHRNB2 1324/4885CHRNB4 1365/4885CHRNA3 488/4885 |
| US-20210163445-A1 | CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS | UCK2, ULK2, CDK9 | CHRNB2 4796/4885CHRNB4 4823/4885CHRNA3 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.